Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Galmed Pharmaceuticals Ltd. GLMD
$0.33
-$0.04 (-11.21%)
На 18:00, 12 мая 2023
+1 415.15%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
9158916.00000000
-
week52high
0.95
-
week52low
0.29
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.12629700
-
EPS
-0.73000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Hold | Buy | 08 авг 2022 г. |
| Canaccord Genuity | Hold | Buy | 08 авг 2022 г. |
| Raymond James | Market Perform | Outperform | 18 мая 2022 г. |
| Raymond James | Outperform | Outperform | 03 мая 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 03 мая 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
InvestorPlace
05 мая 2023 г. в 08:57
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equity investment in OnKai.
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
14 сент 2022 г. в 13:29
Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.